Q2 Financial Highlights 2020 vs 2019: SaaS revenue of $17.5 million vs $18.3 million Total gross margin of 58%, up from 56% In July 2020 , acquired OpenNMS Group , the world’s premier open source network management company Expands product and service offerings while opening opportunities beyond

CULVER CITY, Calif. --(BUSINESS WIRE)--Aug. 3, 2020-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2020 second quarter on Thursday, August 6, 2020 , after market close.

CULVER CITY, Calif. --(BUSINESS WIRE)--Jul. 27, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the acquisition of The OpenNMS   Group, Inc. ( www.opennms.com ), the world’s premier open-source network management company,

Study Published in JCI Insight sheds light on the importance of using both transcriptomics and genomics for patient tumor interrogation to gain actionable insight CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 25, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized

Findings presented during the developmental therapeutics session at the ASCO 2020 Virtual Scientific Program CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 18, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced the publication of four

NantHealth Announces Eviti Product Updates to Aid Efficiency and Reporting for Payers & NaviNet Product Updates to Enhance the User Experience CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 16, 2020-- NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company,

Providers to benefit from free access to leading payer-provider collaboration platform through May CULVER CITY, Calif. --(BUSINESS WIRE)--May 8, 2020-- NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, will offer free access to the NaviNet AllPayer

    Q1 Financial Highlights 2020 vs 2019: SaaS revenue was $18.1 million , up 2% Total gross margin increased to 60% from 49% Appointed Deanna L. Wise , Senior Vice President and Chief Information Officer for Banner Health , to Board of Directors   Completed Sale of Connected Care Business in

CULVER CITY, Calif. --(BUSINESS WIRE)--May 4, 2020-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2020 first quarter on Thursday, May 7, 2020 , after market close.

New board member brings clinical expertise and IT leadership CULVER CITY, Calif. --(BUSINESS WIRE)-- NantHealth , Inc. ( NASDAQ: NH ), a next-generation, evidence-based, personalized healthcare company, announced today the appointment of Deanna L. Wise , Senior Vice President and Chief Information

Q4 Financial Highlights 2019 vs 2018: Total revenue was $24.2 million , up 6% SaaS revenue was $18.4 million , up 6% Total gross margin increased to 63% from 50% Full-Year Financial Highlights 2019 vs 2018: Total revenue was $96.0 million , up 7% SaaS revenue was $72.8 million , up 11% Total gross

Continued Relationships with Health Insurers Reflect the Need for High-quality, High-value Care as Cancer Treatments Become Increasingly Complex CULVER CITY, Calif. --(BUSINESS WIRE)--Feb. 27, 2020-- NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company,

NantHealth Chairman and CEO Will Reveal How Advancements in AI and Machine Learning are Improving the Diagnosis and Treatment of Cancer ORLANDO, Fla. --(BUSINESS WIRE)--Feb. 25, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare technology company,

CULVER CITY, Calif. --(BUSINESS WIRE)--Feb. 24, 2020-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2019 fourth quarter on Friday, February 28, 2020 , after market close.

Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance CULVER CITY, Calif. --(BUSINESS WIRE)--Feb. 19, 2020-- NantOmics, LLC , the leader in molecular

Findings Presented at the ASCO-SITC 2020 Clinical Immuno-Oncology Symposium Orlando, FL and Culver City, CA – February 19, 2020 – NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in molecular analysis, today announced

Culver City, CA — February 4, 2020 :  NantHealth, Inc.  (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare technology company, today announced it has completed the sale of the company’s Connected Care assets to  Masimo , a global leader in noninvasive monitoring technologies

New Partnership to Enable Cost Savings and Rapid ROI Across the Continuum of Care WHEELING, W. Va. & CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 28, 2020-- NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced its partnership with The

Derived from deep-learning models, the findings demonstrate novel AI methods of identifying tumor-infiltrating lymphocytes (TILs) in lung cancers BURLINGAME, Calif. --(BUSINESS WIRE)--Jan. 27, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium SAN FRANCISCO --(BUSINESS WIRE)--Jan. 25, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced new real-world data on treatment patterns for

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium SAN FRANCISCO --(BUSINESS WIRE)--Jan. 25, 2020-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA

IRVINE, Calif. & CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 14, 2020-- Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies, and NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the signing of a definitive